LFC131 peptide-conjugated polymeric nanoparticles for the effective delivery of docetaxel in CXCR4 overexpressed lung cancer cells

- LFC131 peptide (d-Tyr-Arg-Arg-2-Nal-Gly), an inhibitor of CXCR4-ligand binding, is a low molecular weight CXCR4 antagonist.
- A novel LFC131 peptide surface conjugated O-CMC NP to target CXCR4 over expressed A549 lung cancer cells.
- Targeted NPs induced a greater apoptosis and caspase-3 activity in A549 cancer cells.
- Present nanoplatform could facilitate a treatment protocol for CXCR4 overexpressing A549 lung cancer cells.